{
    "Trade/Device Name(s)": [
        "CONTOUR\u00ae NEXT ONE Blood Glucose Monitoring System",
        "CONTOUR\u00ae NEXT USB Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care",
    "510(k) Number": "K160682",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150942"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "LFR"
    ],
    "Summary Letter Date": "November 4, 2016",
    "Summary Letter Received Date": "November 7, 2016",
    "Submission Date": "November 10, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CONTOUR\u00ae NEXT ONE blood glucose meter",
        "Mobile smart device (via CONTOUR Diabetes app)"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "FAD-GDH enzymatic reaction",
        "Bluetooth Low Energy communication"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "App"
    ],
    "Document Summary": "FDA 510(k) summary for CONTOUR\u00ae NEXT ONE blood glucose monitoring system featuring Bluetooth connectivity and quantitative glucose measurement",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertips or palm by a single user for self-testing outside the body to aid monitoring effectiveness of a diabetes control program; not for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}